Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	3.65B
Revenue (ttm)	434.25M
Net Income (ttm)	-606.64M
Shares Out	82.34M
EPS (ttm)	-8.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	520,412
Open	45.52
Previous Close	45.11
Day's Range	43.61 - 45.55
52-Week Range	31.52 - 54.98
Beta	0.66
Analysts	Strong Buy
Price Target	88.07 (+98.98%)
Earnings Date	May 2, 2024

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and ad...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,276
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE

Financial Performance

In 2023, RARE's revenue was $434.25 million, an increase of 19.52% compared to the previous year's $363.33 million. Losses were -$606.64 million, -14.25% less than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price forecast is $88.07, which is an increase of 98.98% from the latest price.

Price Target

$88.07

(98.98% upside)

Analyst Consensus: Strong Buy